Abstract Most evidence for the health benefits of prescribing caloric restriction (CR) for weight loss is derived from randomized, controlled trials (RCTs) in young/middle-aged adults; there are very few RCTs in older adults in which the isolated effects of CR can be deciphered. The purpose of this review is to summarize the RCT evidence of the benefits (and potential risks) of CR for the treatment of obesity in older adults. We identified only 19 published papers from 10 RCTs ranging from 3 to 18 months that met the criteria of independent effects of a CR component and were conducted in adults with a mean age ≥65 years. Overall, the results show a beneficial treatment effect for improving some metabolic, functional, and body composition outcomes with few documented risks. However, all outcomes were assessed immediately after treatment cessation. Thus, until additional scientifically rigorous evidence with long-term follow-up is available; the riskto-benefit ratio of CR for the treatment of obesity in older adults remains unclear.
Introduction
Obesity is a chronic disease that affects individuals of all ages. Treatment of obesity, through modifications in diet and physical activity behavior that cause reductions in body weight, markedly improves individual cardiometabolic risk and reduces collective incidence of metabolic syndrome and type 2 diabetes [1] [2] [3] . However, the vast majority of evidence for the health benefits of weight loss is derived from randomized, controlled trials (RCTs) conducted in young to middle-aged adults (e.g., <65 years). Thus, treating obesity in young-old (e.g., 65-74 years), and especially in old (those greater than 75 years), adults is controversial given the dearth of RCTs conducted in this population, the lack of consensus regarding the health risks associated with obesity in this age group, the uncertain long-term benefits of intentional weight loss, and the potentially harmful effects of weight loss on muscle mass and bone mineral density [4-6, 7•, 8] . Hence, the purpose of this review is to summarize the RCT evidence of the health benefits and risks resulting from reducing caloric intake to treat obesity in older adults. We focused solely on trials designed to elicit weight loss via caloric restriction (CR) since the health benefits of exercise are evident in this age group [9] .
The Aging, Obese Population
In the 4th century BC, Plato divided the human lifespan into six phases, the last two constituting BOld Age^ (62-79 years) and BAdvanced Age (80+ years)^. The last phase, he noted, Bis one that, fortunately, few attain^ [10] . This statement is less true in the 21st century, as both the proportion of older people and maximal lifespan are increasing [11] . According to the United States Census Bureau, about 27 million people are young-old (65-74 years) and 20 million are old-old (75+ This article is part of the Topical Collection on Nutrition and Aging * Barbara J. Nicklas bnicklas@wakehealth.edu years), and these numbers are expected to nearly double by 2030 [12] . Moreover, people are living longer (life expectancy for women is 81.2 years and for men is 76.4 years [13, 14] ) and can expect to live nearly 20 years in Plato's defined Bold age^phase of life. Fortunately, most individuals in their 60s and 70s are healthy and still functional and able to care for themselves. In fact, disability trends are decreasing even as life expectancy is increasing [15, 16] . Whereas the major health threats of earlier generations were infectious and parasitic disease, currently, chronic diseases, such as heart disease and cancer (the current leading causes of death), are more common and impose the greatest burden on global health [11, 14] . Unfortunately, the trends for increased life expectancy with decreased disability may not continue or could be reversed in future generations, in part because of the rising prevalence of obesity among all ages. Obesity, operationalized as a body mass index (BMI)≥30 kg/ m 2 , leads to a higher risk of numerous chronic illnesses and premature death in young and middle-aged adults [17, 18] . Thus, the increase in obesity over the past half-century [19] may potentially limit growth in life expectancy [20] . Data from the 2007-2010 U.S. National Health and Nutrition Examination Survey showed that 34.6 % of adults 65+ years, and 27.8 % of those 75+ years, were obese [21] . Alarmingly, this is a nearly 10 % increase since 1999-2003, illuminating the effects of the shifting age demographics on the prevalence of obesity among the geriatric population. Since obesity is a major risk factor for disability [22•] , the growing prevalence of obesity in this age group could lead to a reversal of improved disability trends.
Defining Obesity in Older Adults
The condition and diagnoses of obesity should be applied to individuals with excess accumulation of adipose tissue to the extent that health is impaired. The current World Health Organization classification of obesity is based on BMI cut-points that are associated with increased mortality and risk for type 2 diabetes and cardiovascular disease (CVD) [23] . However, this definition of obesity may not be as applicable in older adults for at least two reasons: (1) BMI is a crude measure of adiposity, especially in older people in whom stature and body composition are changing, nor does it account for the wide variation in location of body fat which poses even stronger health risks than total adiposity [24, 25] ; and (2) the adverse consequences of excess adipose tissue may extend beyond chronic disease and early mortality in this age group. Thus, there is potential misclassification of the health risks related to obesity in older adults using the current standards.
Aging is characterized by considerable changes in body composition, most notably, a loss of skeletal muscle mass (sarcopenia) [26, 27] and gain and redistribution of fat to less desirable locations (i.e., within the abdominal cavity and muscle) [28] . The combination of sarcopenia and fat mass accumulation in an aging population, known as sarcopenic obesity [29] , may be a stronger risk factor than BMI in this population, as it is associated with higher morbidity, mortality, and disability [30] [31] [32] . In addition, waist circumference may be as good as, or even better, than BMI as a measure of excess adiposity in older adults [33] [34] [35] [36] . However, more data are needed to accurately determine appropriate cut-points of sarcopenic obesity and/or waist circumference that are more closely associated with impaired health than BMI. These data are critical for identifying those older adults for whom the benefits of weight loss would outweigh potential treatment risks.
Caloric Restriction for the Treatment of Obesity in Older Adults: What Is the Evidence?
The recently updated treatment guidelines for managing obesity in adults recommend an intensive lifestyle intervention involving behavioral counseling, caloric restriction (CR), and regular exercise to achieve weight loss for adults of all ages [3] . However, this report also acknowledges that available literature does not address whether age modifies the benefits of weight loss and that Bthere is a need for further research to understand the most appropriate strategies and prescriptions for weight loss for some key populations, including older adults^ [3] . Furthermore, although a position statement by the American Society for Nutrition and The Obesity Society from a decade ago stated that B…current data show that weight-loss therapy improves physical function, quality of life, and the medical complications associated with obesity in older persons,^the authors acknowledged that most of the studies they reviewed were conducted primarily in middleaged persons (ages 40-65 years at baseline) [37] . Thus, the risk-to-benefit ratio of obesity treatment (e.g., CR for weight loss) remains controversial in older adults. Here, we summarize the entirety of the published scientific evidence from RCTs comparing a CR treatment to a control group (to allow for isolation of the independent effects of the CR/diet component) that were conducted in adults with a mean age ≥65 years. We identified 19 published papers from 10 RCTs (Table 1) with a combined sample size of 1981 (range of n=22 to n= 585) [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] 50 . The treatments ranged from CR alone (achieved through behavioral counseling, meal replacements, or controlled feeding interventions) to CR plus exercise training that were compared to a control group that consisted of usual care (e.g., no intervention) or to an identical exercise training intervention without CR. For this review, we only summarize the main effects of the CR/diet treatment. Treatment duration ranged from 3 to 18 months, and the degree of weight loss achieved in the Abdominal Fat The accumulation of abdominal fat, especially within the abdominal cavity (visceral) [58] , is more strongly associated with insulin resistance [59] , hyperlipidemia [59, 60] , hypertension, and low-grade inflammation [61] than total adiposity. Therefore, decreasing abdominal fat in older adults may have important beneficial effects on risk factors for diabetes and CVD [62] . Four trials show an independent effect of CR on some index of abdominal fat [43, 47, 54••, 55] , but results do not show a preferential loss of visceral adipose tissue.
Thigh Fat Content A decrease in intermuscular fat may also be clinically relevant in older adults since excess fat within leg muscles is the strongest body composition predictor of impaired physical function in older individuals [63, 64] . Six trials examined the effect of CR on total thigh fat [47, 48, 55, 56 •], subcutaneous and intermuscular fat [47, 55, 56 •], and/or intramyocellular lipid content of thigh muscle [42, 45] in older adults. The addition of CR to exercise decreased total and/or subcutaneous thigh fat in four studies [47, 48, 55, 56 •]; however, interestingly, no significant independent effect of CR on the magnitude of intermuscular fat was observed in any trial [47, 56•] . As for intramyocellular lipid content, one small study found that, despite a greater loss of body mass in the CR with exercise group, intramyocellular lipid decreased as much in the exercise only group [42] . However, another small AUC area under the curve, BP blood pressure, BMD bone mineral density, Chol cholesterol, CR caloric restriction, CVD cardiovascular disease, EX exercise, FM fat mass, HDL-chol high density lipoproteins, HOMA-IR homeostasis model assessment of insulin resistance, CRP C-reactive protein, IL-6 interleukin-6, PPT physical performance, IL-6sR IL-6 soluble receptor, IMAT intermuscular adipose tissue, IMCL intramyocellular lipids, LM lean mass, LDL low density lipoproteins, mos months, OGTT oral glucose tolerance test, SPPB short physical performance battery, sTNFR1 soluble TNF-α receptor 1, sTNFR2 soluble TNF-α receptor 2, SAT subcutaneous adipose tissue, TG triglycerides, TNF-α tumor necrosis factor alpha, VAT visceral adipose tissue, wks weeks, WL weight loss, 1-RM onerepetition maximum study showed separate effects of CR and exercise on intramyocellular lipid [45] ; they observed that an 8 % decrease in body mass with CR corresponded to a 16 % decrease in intramyocellular lipid, whereas a 2 % decrease in body mass with exercise corresponded to a 40 % increase in intramyocellular lipid. Obviously, more data are needed before any definitive conclusions can be made regarding the effects of diet-induced weight loss on fat accumulation between and within skeletal muscle in this age group.
Effects of Treatment on Physical Function
Obesity strongly predisposes individuals to the onset of mobility disability, which is one of the most costly complications of obesity in this age group [65, 66] . Studies consistently show that elevated BMI in older women and men is strongly associated with the presence of poor function and future decline in physical performance or the development of disability [67, 68] . Obesity-associated inflammatory milieu, sarcopenia, and impairment of muscle function are important contributing factors through which obesity poses a threat to earlier onset of disability with aging [31, 32, 69] . Although obesity is an important risk factor for disability in older adults, to date, only a handful of RCTs have quantified the effectiveness of CR on physical function in older individuals [40, 46-48, 51••, 56•] . The results of these trials are difficult to compare due to the variable direct and indirect approaches used to measure physical function and differences in the initial health of participants. Four trials examined the effects of a CR intervention on self-reported functional ability [40, 48, 51••, 56•] , and all demonstrate an independent main effect of CR, though all of these interventions also included an exercise component. Notably, two of these trials showed no difference in self-reported function between CR alone and exercise alone [48, 51••] , indicating that the exercise component may be just as effective, at least for subjective measures of function. Several trials also examined the effects of CR on objective measures of function [40, 46-48, 51••, 56•] . Two of these did not observe an additive effect of adding CR to exercise compared to exercise alone for overall function assessed by a battery of tests [47, 56•] , whereas one trial did observe an additive improvement in overall function with CR and exercise compared to exercise alone [48] . None of the trials point to an independent main effect of CR on muscle strength or gait speed [48, 56•] . However, adding CR to exercise (either aerobic or resistance) improves mobility as assessed by longdistance walk tests [46, 51••, 56•] ; yet, two trials showed that CR alone does not improve mobility more than exercise alone [40, 51••] , or compared to a control group [40] . Hence, adding CR to an exercise intervention seems to improve mobility/ endurance and self-reported functional ability, but there is less evidence for a beneficial independent effect of CR on other measures of physical function.
Effects of Treatment on Inflammation and Cardiometabolic Health
Numerous studies show that obesity, especially excess abdominal fat, leads to dyslipidemia and insulin resistance, along with other metabolic disturbances, including chronic inflammation, even in old age [34, 70, 71] . Four RCTs examined the effects of CR on inflammation in older adults [ There is no doubt that CR interventions resulting in weight loss cause improvements in insulin sensitivity in younger individuals [72] . However, results from the few intervention trials that examined this outcome in older adults are inconsistent. There were three trials with small samples (Ns<25) that assessed insulin sensitivity directly with a euglycemic clamp, and the results do not show a difference of adding CR to an exercise intervention compared to exercise alone in this age group [42, 43, 45] . However, two trials show an independent effect of CR for improving fasting measures of glucose control [54••, 45] . While both the Diabetes Prevention Program and the Look AHEAD trial showed a beneficial effect of lifestyle intervention for reducing diabetes risk and related risk factors in older adults (60+ years), these interventions were a combination of CR and physical activity and the independent effects of the CR component cannot be isolated [73, 74] . Thus, the four trials identified here are the only ones, to date, that examined whether there is an independent effect of adding CR to a lifestyle intervention for improving insulin sensitivity or glucose control.
Experimental studies that evaluated the efficacy of CR on blood pressure and lipid risk factors in older adults are even more scarce. The Trial of Non-Pharmacological Interventions in the Elderly (TONE) [38] provides convincing evidence for a beneficial effect of CR on blood pressure and decreased need for antihypertensive medication use in older patients with hypertension. A different trial found a beneficial effect of CR for systolic blood pressure only, but not all participants in this trial were hypertensive [54••] . Finally, a smaller study did not show a reduction in blood pressure from CR plus exercise compared to exercise alone [43] . Notably, only two trials examined independent effects of CR on blood lipids in older adults and both showed no effect of CR on total cholesterol, LDL-cholesterol, HDL-cholesterol, or triglycerides [43, 54••] . Obviously, very few well-powered trials have been conducted to clearly answer how diet-induced weight loss affects cardiometabolic risk factors in older adults, and there is a critical need for future larger, well-designed RCTs.
Effects of Treatment on Longevity
Data from observational studies show that weight loss is associated with increased risk of mortality in older adults [75] [76] [77] ; however, these studies cannot definitively resolve whether the weight loss was intentional or not. A follow-up of two of the larger RCTs (TONE and ADAPT) conducted by Shea et al. specifically examined the effects of randomization to CR for weight loss on mortality [44, 49] . In the first study, after 8 years of follow-up, the total mortality rate was 50 % lower in those assigned to CR compared to control [44] . In the second study, there was no difference in all-cause mortality between adults assigned to CR and those who were not [49] . Hence, these data indicate that intentional weight loss via CR is not associated with an increased mortality risk; however, additional RCTs are necessary to validate these results.
Risks of Obesity Treatment in Older Adults
Despite evidence that obesity contributes to functional decline and disability, there are potential benefits associated with being overweight or obese in old age. Observational data show that unintentional weight loss is associated with increased disability [78, 79] . In addition, overweight and mild obesity are associated with protection against osteoporosis and fractures [80] , with better prognostic recovery from certain illness and injuries [81] , and with reduced mortality risk [81] in older adults. A position statement from The Obesity Society states that Bappropriate treatment for obesity in older persons is controversial because of the reduction in relative health risks associated with increasing BMI and the concern that weight loss could have potential harmful effects^ [37] . Moreover, based on clinical judgment, many geriatricians strongly advocate that recommending CR for weight loss in their older patients will be harmful in the long run [82, 83] . Thus, it is important to clarify the extent to which diet-induced weight loss affects these proposed health benefits of overweight/ obesity in older adults.
Yet, there is essentially no long-term health outcome data from RCTs of diet-induced weight loss in older adults. All of the reported benefits of CR listed in Table 1 were examined immediately after completion of the intervention, and there are no controlled data on the long-term effects of treatment on intermediate endpoints (body composition/fat distribution, physical function, or cardiometabolic risk) or disease incidence or prognosis. Therefore, presently, there is a lack of definitive evidence of any long-term risks of prescribing CR for weight loss in adults ≥65 years; however, we summarize below the available data on the effects of CR on loss of muscle and bone density, which are important risk factors for agingrelated sarcopenia, frailty, and fractures.
Effects of Treatment on Lean (Muscle) Mass and Sarcopenia
There is a prevailing concern that weight loss may worsen age-related loss of muscle that leads to sarcopenia [84] . Data from the RCTs in Table 1 , in all trials, the majority of total mass lost was fat. Thus, relative sarcopenia (muscle mass to body weight) is reduced despite this absolute loss of muscle, indicative of overall favorable changes in body composition with CR in older adults. Other trials show that there are strategies (such as performing resistance exercise, increasing protein intake, or losing weight at a slower pace) that reduce the amount of lean mass lost during CR [85] . However, these strategies do not totally prevent loss of muscle with weight loss-thus, it is important to identify the long-term ramifications of this loss of muscle.
Since aging is associated with loss of muscle and gain in fat, a cycle of weight loss and subsequent regain may exacerbate sarcopenia over time if lean mass is not recovered. Some early data are beginning to show a preferential accumulation of fat over lean mass during weight regain following intentional weight loss [86] . In fact, in three studies, weight regain following weight loss was comprised entirely of fat in middleaged to older adults [87] [88] [89] . Observational data also show proportionally more lean mass is lost during periods of weight loss than is gained during periods of weight gain or regain [90, 91] , and that weight cycling increases the risk for physical disability [92] . Thus, since maintenance of lost weight is extremely difficult due, in part, to the biological adaptations that occur for the evolutionary purpose of defending existing energy stores [93, 94] , an obesity treatment involving CR that leads to short-term weight loss followed by weight gain could accelerate sarcopenia over time in older adults. However, presently, there are no RCT data to support or refute this hypothesis.
Effects of Treatment on Bone Mineral Density, Osteopenia/Osteoporosis, and Fracture Risk A potential beneficial effect of obesity in late life is protection from osteoporosis-related fractures [95•] . Obesity, which increases weight-bearing stress on the skeleton, is associated with greater bone mineral density (BMD) [96] , and fat around the trochanter can protect against hip fracture during a fall [95•] . Thus, a concern is that weight loss may have deleterious effects in older adults by causing bone loss on top of agerelated bone loss [97] .
Four of the trials analyzed the independent effects of CR on BMD [39, 47, 48, 52••] . Two of them found that CR decreased BMD in the hip, but not the spine region, and that the decrease in hip BMD correlated with the magnitude of weight lost [48, 52••] . The other two trials either did not observe a significant decline in BMD [47] , or did not observe a significantly different decline in BMD between the CR and control groups [39] . As indicated by Beavers et al. [52••] , even though the CR intervention decreased hip BMD, the clinical classification of osteoporosis and osteopenia remained unchanged. Thus, whether the magnitude of BMD loss observed in these trials translates into osteopenia, osteoporosis, and increased fracture risk remains to be determined.
Conclusion
Presently, there are no evidence-based treatment guidelines to inform clinicians on the proper management of geriatric obesity. Guidelines geared towards younger populations should not automatically apply to older adults in view of the unique health concerns of this population. Given the unarguable benefits of exercise on both physical function and metabolic health, even in older adults with obesity, the real question of interest is whether obesity treatment via a dietary intervention that encourages or enforces CR is effective and whether its benefits outweigh any risks. The evidence summarized here is from the most rigorously designed and scientifically valid research to date that will inform age-specific treatment guidelines-that is randomization of older adults (65+ years) to either: (1) an intervention that included a diet component targeting reduced caloric intake or (2) a control intervention that did not receive the diet component (to allow for isolation of the effects of CR versus exercise).
Overall, the results show a treatment effect of CR for improving some metabolic and functional outcomes with few documented risks. However, there are confounding factors that must be noted which make it difficult to interpret the results and definitively recommend CR as an effective obesity treatment in older adults. First, several of the trials were likely underpowered as only five of them randomized more than 50 individuals per group (TONE, ADAPT, CLIP, IDEA, I'M FIT). Second, it is impossible to discern whether some of the observed treatment effects of the CR group were due to weight loss per se, since in several trials, the control (non-CR) group lost weight also, even losing as much as 50 % of the weight loss seen in the treatment group. Third, the CR interventions used across trials were highly variable and many altered dietary composition or nutrient intake in addition to caloric intake. Next, although we limited this review to RCTs that used a sample with a mean age ≥65 years, all were within a very small mean age range of 65-70 years. Clearly, more research is needed that either reports the independent effects of CR in subgroups that are older or are de novo trials that recruit individuals in their 7th and 8th decades of life. Finally, all of the available RCTs only provide data on health outcomes assessed immediately after treatment cessation. There is a critical need for additional research in this area that focuses on the longterm health benefits and risks of prescribing CR to induce weight loss for the treatment of geriatric obesity.
